January 2016 - In the News - FDA Updates

The U.S. Food and Drug Administration today approved a new indication for the Integra Omnigraft Dermal Regeneration Matrix (Omnigraft) to treat certain diabetic foot ulcers. The matrix device, which is made of silicone, cow collagen, and shark cartilage, is placed over the ulcer and provides an environment for new skin and tissue to regenerate and heal the wound.

An estimated 29 million people in the United States have been diagnosed with diabetes, according to the Centers for Disease Control and Prevention, and about 25 percent of them will experience a foot ulcer during their lifetime. Chronic diabetic foot ulcers are associated with tissue and bone infections and result in 50,000 amputations each year.

“We are excited to see a new innovation in diabetes care with the potential to improve the number of foot ulcers that heal,” said William Maisel, M.D., M.P.H., acting director of the Office of Device Evaluation in the FDA’s Center for Devices and Radiological Health. “Healing of these painful and debilitating ulcers is essential for patients to resume walking and other daily activities.”

The FDA first approved Integra Dermal Regeneration Template (which the company now also calls Omnigraft) in 1996 for the treatment of life threatening burn injuries when the use of a patient’s own skin for a graft was not possible. In 2002, Integra Dermal Regeneration Template was approved for a new indication to treat patients undergoing reconstructive surgery for burn scars when they cannot have skin grafts. Now, Omnigraft is approved to treat certain diabetic foot ulcers that last for longer than six weeks and do not involve exposure of the joint capsule, tendon or bone, when used in conjunction with standard diabetic ulcer care.

Omnigraft’s new indication is based on a clinical study that demonstrated that the matrix device improved ulcer healing compared to standard diabetic foot ulcer care, which includes cleaning and covering the wound with a surgical bandage and keeping weight off of the foot with the ulcer. In the study, 51 percent of patients treated with Omnigraft had healed ulcers after 16 weeks compared to 32 percent of patients treated with standard diabetic foot ulcer care alone.

Adverse events observed in the clinical trial included infections, increased pain, swelling, nausea, and new or worsening ulcers.

Omnigraft shouldnot be used in patients with allergies to cow (bovine) collagen or chondroitin (cartilage from any source) since serious allergic reactions may occur. Omnigraft should also not be used on infected wounds.

Omnigraft is manufactured by Integra LifeSciences Corporation of Plainsboro, New Jersey.

US Food and Drug Administration. FDA approves Integra Omnigraft Dermal Regeneration Matrix to treat diabetic foot ulcers. Updated January 7, 2016.

Related Items
Once-Daily Injection Approved for Patients with Type 2 Diabetes
July 2016 - In the News published on July 29, 2016 in FDA Updates
First Oral Regimen FDA Approved for Treatment of Chronic HCV
June 2016 - In the News published on June 29, 2016 in FDA Updates
FDA Approves First Generic Version of Crestor for Multiple Indications in Adults
May 2016 - In the News published on May 25, 2016 in FDA Updates
Nuplazid Approved for Psychosis-Associated Hallucinations in Patients with Parkinson’s Disease
May 2016 - In the News published on May 25, 2016 in FDA Updates
FDA Enhances Warnings for Serious Risks of Opioid Analgesics Abuse
April 2016 - In the News published on April 26, 2016 in FDA Updates
Obiltoxaximab FDA-Approved to Treat and Prevent Inhalation Anthrax
March 2016 - In the News published on March 24, 2016 in FDA Updates
FDA Approves Briviact to Treat Partial Onset Seizures
March 2016 - In the News published on March 21, 2016 in FDA Updates
FDA Approves First Coagulation Factor-Albumin Fusion Protein to Treat Patients with Hemophilia B
March 2016 - In the News published on March 21, 2016 in FDA Updates
FDA Approves Basaglar, the First “Follow-On” Insulin Glargine Product to Treat Diabetes
January 2016 - In the News published on January 6, 2016 in FDA Updates
FDA Approves Wearable Defibrillator for Children at Risk for Sudden Cardiac Arrest
January 2016 - In the News published on January 6, 2016 in FDA Updates
Last modified: January 12, 2016
  • American Health & Drug Benefits
  • The Journal of Hematology Oncology Pharmacy
  • Lynx CME
  • The Oncology Pharmacist

Search